Anti-HIgG(Fc)Fab-C-DX8951 ADC (CAT#: ADC-AA-062)

A: Exatecan mesylate (DX8951) is a potent topoisomerase I inhibitor used in this ADC to disrupt DNA replication and transcription processes in targeted cells. By inhibiting topoisomerase I, DX8951 induces DNA damage, leading to cell cycle arrest and apoptosis in cancer cells expressing human IgG Fc.

A: Creative Biolabs conducts extensive testing to validate the specificity, stability, and cytotoxic efficacy of the ADC. This includes binding assays, in vitro cytotoxicity tests, and stability assessments to ensure that the product meets rigorous standards required for high-quality research applications.

A: Due to the cytotoxic nature of DX8951, researchers must follow strict safety protocols, including handling the ADC with care, using appropriate personal protective equipment, and disposing of ADC-related materials according to hazardous waste guidelines.

A: Creative Biolabs recommends using this ADC in models that express human IgG Fc, such as humanized mouse models of cancer or in vitro cancer cell lines. These models help in assessing the ADC's efficacy in targeting and killing cancer cells, providing valuable data for preclinical research.

A: Research findings could provide insights into developing more effective ADC-based therapies for treating cancers that express human IgG Fc. This ADC serves as a platform to explore and refine ADC technology, potentially guiding future clinical ADC designs for targeted cancer therapy.